Literature DB >> 29978432

Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma.

Kentaro Narita1, Hiroki Kobayashi1, Yoshiaki Abe1, Hiroaki Kitadate1, Masami Takeuchi1, Kosei Matsue2.   

Abstract

We examined the association of residual bone-marrow plasma cells (PCs) and International Myeloma Working Group (IMWG) response assessment in light-chain-only multiple myeloma (LCMM) and intact immunoglobulin multiple myeloma (IIMM) using multicolour flow cytometry (MFC). We identify considerable differences in bone-marrow neoplastic PC levels between IIMM and LCMM for the same IMWG response categories. Furthermore, even in the same IMWG response category, residual neoplastic PC levels differed considerably over a logarithmic scale range However, normalization of the free light-chain ratio is associated with deeper response (< 10-4) in LCMM, but not in IIMM. Our observations highlight the importance of quantifying BM PC by MFC for response assessment, especially for relapsed disease when there is suspected discrepancy in paraprotein levels and disease progression.

Entities:  

Keywords:  IMWG response criteria; MRD; Multicolor flow cytometry; Myeloma

Mesh:

Year:  2018        PMID: 29978432     DOI: 10.1007/s12185-018-2489-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Frequency of altered monoclonal protein production at relapse of multiple myeloma.

Authors:  Josie A R Hobbs; Mark T Drayson; Katie Sharp; Stephen Harding; Arthur R Bradwell; Graham P Mead
Journal:  Br J Haematol       Date:  2009-10-26       Impact factor: 6.998

2.  Prevalence and monitoring of oligosecretory myeloma.

Authors:  Dirk Larson; Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

3.  Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma.

Authors:  Bruno Paiva; Joaquin Martinez-Lopez; Maria-Belen Vidriales; Maria-Victoria Mateos; Maria-Angeles Montalban; Elena Fernandez-Redondo; Lourdes Alonso; Albert Oriol; Ana-Isabel Teruel; Raquel de Paz; José-Garcia Laraña; Enrique Bengoechea; Alejandro Martin; Joaquin Diaz Mediavilla; Luis Palomera; Felipe de Arriba; Joan Bladé; Alberto Orfao; Juan-Jose Lahuerta; Jesus F San Miguel
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

4.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

5.  Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

Authors:  Thomas Dejoie; Jill Corre; Helene Caillon; Cyrille Hulin; Aurore Perrot; Denis Caillot; Eileen Boyle; Marie-Lorraine Chretien; Jean Fontan; Karim Belhadj; Sabine Brechignac; Olivier Decaux; Laurent Voillat; Philippe Rodon; Olivier Fitoussi; Carla Araujo; Lotfi Benboubker; Charlotte Fontan; Mourad Tiab; Pascal Godmer; Odile Luycx; Olivier Allangba; Jean-Michel Pignon; Jean-Gabriel Fuzibet; Laurence Legros; Anne Marie Stoppa; Mamoun Dib; Brigitte Pegourie; Frederique Orsini-Piocelle; Lionel Karlin; Bertrand Arnulf; Murielle Roussel; Laurent Garderet; Mohamad Mohty; Nathalie Meuleman; Chantal Doyen; Pascal Lenain; Margaret Macro; Xavier Leleu; Thierry Facon; Philippe Moreau; Michel Attal; Herve Avet-Loiseau
Journal:  Blood       Date:  2016-10-11       Impact factor: 22.113

6.  Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.

Authors:  Bruno Paiva; Maria-Teresa Cedena; Noemi Puig; Paula Arana; Maria-Belen Vidriales; Lourdes Cordon; Juan Flores-Montero; Norma C Gutierrez; María-Luisa Martín-Ramos; Joaquin Martinez-Lopez; Enrique M Ocio; Miguel T Hernandez; Ana-Isabel Teruel; Laura Rosiñol; María-Asunción Echeveste; Rafael Martinez; Mercedes Gironella; Albert Oriol; Carmen Cabrera; Jesus Martin; Joan Bargay; Cristina Encinas; Yolanda Gonzalez; Jacques J M Van Dongen; Alberto Orfao; Joan Bladé; Maria-Victoria Mateos; Juan José Lahuerta; Jesús F San Miguel
Journal:  Blood       Date:  2016-04-26       Impact factor: 22.113

Review 7.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

8.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777

9.  Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

Authors:  J Flores-Montero; L Sanoja-Flores; B Paiva; N Puig; O García-Sánchez; S Böttcher; V H J van der Velden; J-J Pérez-Morán; M-B Vidriales; R García-Sanz; C Jimenez; M González; J Martínez-López; A Corral-Mateos; G-E Grigore; R Fluxá; R Pontes; J Caetano; L Sedek; M-C Del Cañizo; J Bladé; J-J Lahuerta; C Aguilar; A Bárez; A García-Mateo; J Labrador; P Leoz; C Aguilera-Sanz; J San-Miguel; M-V Mateos; B Durie; J J M van Dongen; A Orfao
Journal:  Leukemia       Date:  2017-01-20       Impact factor: 11.528

10.  Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Authors:  Andy C Rawstron; Walter M Gregory; Ruth M de Tute; Faith E Davies; Sue E Bell; Mark T Drayson; Gordon Cook; Graham H Jackson; Gareth J Morgan; J Anthony Child; Roger G Owen
Journal:  Blood       Date:  2015-02-02       Impact factor: 22.113

View more
  1 in total

1.  Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria.

Authors:  Kentaro Narita; Daisuke Miura; Takafumi Tsushima; Toshiki Terao; Ayumi Kuzume; Rikako Tabata; Masami Takeuchi; Kosei Matsue
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.